{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:21:56Z","timestamp":1790907716443,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1016\/j.jconrel.2005.02.028","type":"journal-article","created":{"date-parts":[[2005,5,25]],"date-time":"2005-05-25T07:49:43Z","timestamp":1117007383000},"page":"185-198","source":"Crossref","is-referenced-by-count":180,"title":["Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice"],"prefix":"10.1016","volume":"105","author":[{"given":"L.","family":"Harivardhan Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.K.","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Chuttani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.K.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.S.R.","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2005.02.028_bib1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0168-3659(97)00185-5","article-title":"Pharmacokinetic characteristics and therapeutic effects of mitomycin C-dextran conjugates after intratumoral injection","volume":"52","author":"Nomura","year":"1998","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2005.02.028_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-5173(02)00543-4","article-title":"BCNU-loaded poly (d,l-lactide-co-glycolide) wafer and antitumor activity against XF-498 human CNS tumor cells in vitro","volume":"251","author":"Seong","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2005.02.028_bib3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0168-3659(01)00309-1","article-title":"Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of prototype polymeric drug SMANCS*","volume":"74","author":"Maeda","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2005.02.028_bib4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0168-3659(01)00341-8","article-title":"Development of the polymer micelle carrier system for doxorubicin","volume":"74","author":"Nakanishi","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2005.02.028_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0378-5173(02)00580-X","article-title":"Pharmacokinetics and antitumor effects of vincristine carried by microemulsions composed of PEG-lipid, oleic acid vitamin E and cholesterol","volume":"251","author":"Junping","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2005.02.028_bib6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0168-3659(02)00262-6","article-title":"Drug delivery in pluronic micelles: effect of high-frequency ultrasound on drug release from micelles and intracellular uptake","volume":"84","author":"Marin","year":"2002","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2005.02.028_bib7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0378-5173(02)00483-0","article-title":"Biodegradable poly(\u025b-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen","volume":"249","author":"Chawla","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2005.02.028_bib8","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jconrel.2003.08.005","article-title":"Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles","volume":"93","author":"Vauthier","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2005.02.028_bib9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0168-3659(03)00241-4","article-title":"Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors","volume":"91","author":"Williams","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2005.02.028_bib10","first-page":"62","article-title":"Solid lipid nanoparticles (SLN)\u2014an alternative colloidal drug carrier system for controlled drug delivery","volume":"41","author":"Muller","year":"1995","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2005.02.028_bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0168-3659(94)90047-7","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery: I. Production, characterization and sterilization","volume":"30","author":"Schwarz","year":"1994","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2005.02.028_bib12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0168-3659(97)01653-2","article-title":"Solid lipid nanoparticles (SLN) as potential carrier for human use: interaction with human granulocytes","volume":"47","author":"Muller","year":"1997","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2005.02.028_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3109\/10611869609015973","article-title":"Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with Poloxamine 908 and Poloxamer 407","volume":"4","author":"Muller","year":"1996","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2005.02.028_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0005-2736(93)90115-G","article-title":"Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection","volume":"1150","author":"Allen","year":"1993","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2005.02.028_bib15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0168-3659(96)01588-X","article-title":"Potential for lymphatic targeting of peptides","volume":"46","author":"Muranishi","year":"1997","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2005.02.028_bib16","first-page":"245","article-title":"Emulsion and activated carbon in chemotherapy CRC","volume":"2","author":"Takahashi","year":"1985","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"key":"10.1016\/j.jconrel.2005.02.028_bib17","first-page":"333","article-title":"Drug delivery to the lymphatic system","volume":"14","author":"Porter","year":"1997","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"key":"10.1016\/j.jconrel.2005.02.028_bib18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF01053934","article-title":"Recurrent brainstem gliomas treated with oral VP-16","volume":"15","author":"Chamberlain","year":"1993","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.jconrel.2005.02.028_bib19","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.1996.14.6.1922","article-title":"Response of recurrent medulloblastoma to low-dose oral etoposide","volume":"14","author":"Ashley","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2005.02.028_bib20","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0005-2736(97)00275-7","article-title":"Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: IV. Fate of liposomes in regional lymph nodes","volume":"1370","author":"Oussoren","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2005.02.028_bib21","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/jps.2600740902","article-title":"Lymphatic transport of liposome encapsulated agents: effect of liposome size following intraperitoneal administration","volume":"9","author":"Hirano","year":"1985","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2005.02.028_bib22","first-page":"283","article-title":"Long-circulating and target-specific nanoparticles: theory to practice","volume":"53","author":"Moghimi","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jconrel.2005.02.028_bib23","first-page":"187","article-title":"Preparation, characterization and biodistribution of 99mTc-labeled liposome encapsulated cyclosporine","volume":"11","author":"Arulsudar","year":"2003","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2005.02.028_bib24","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1042\/bst0050290","article-title":"Properties of [99mTc] technetium labeled liposomes in normal and tumor bearing rats","volume":"5","author":"Richardson","year":"1977","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.jconrel.2005.02.028_bib25","series-title":"Text Book of Radiopharmacy: Theory and Practice","first-page":"127","author":"Theobald","year":"1990"},{"key":"10.1016\/j.jconrel.2005.02.028_bib26","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1358\/mf.2002.24.10.802314","article-title":"Preparation and comparative evaluation of 99mTc-labeled 2-Iminothiolane modified antibodies and CITC-DTPA immunoconjugates of anti-EGF-receptor antibodies","volume":"24","author":"Mishra","year":"2002","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2005.02.028_bib27","first-page":"47","article-title":"Effect of thymosin-alpha1 on the production of nitric oxide by tumor-associated macrophages","volume":"50","author":"Shrivastava","year":"2003","journal-title":"Neoplasma"},{"key":"10.1016\/j.jconrel.2005.02.028_bib28","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/scientificamerican0794-58","article-title":"Barriers to drug delivery in solid tumors","volume":"271","author":"Jain","year":"1994","journal-title":"Sci. Am."},{"key":"10.1016\/j.jconrel.2005.02.028_bib29","first-page":"356","article-title":"Intraperitoneal therapy of ovarian cancer","volume":"25","author":"Markman","year":"1998","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.jconrel.2005.02.028_bib30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s002800050660","article-title":"Bladder tissue pharmacokinetics of intravesical taxol","volume":"40","author":"Song","year":"1997","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2005.02.028_bib31","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/jnci\/81.2.146","article-title":"Distribution and activity of antineoplastic drugs in a tumor model","volume":"81","author":"Durand","year":"1989","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jconrel.2005.02.028_bib32","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/BF02897199","article-title":"Slow penetration of anthracyclines into spheroids and tumors: a therapeutic advantage","volume":"26","author":"Durand","year":"1990","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2005.02.028_bib33","first-page":"871","article-title":"Determinants of paclitaxel penetration and accumulation in human solid tumor","volume":"290","author":"Kuh","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2005.02.028_bib34","first-page":"761","article-title":"Computational model of intracellular pharmacokinetics of paclitaxel","volume":"293","author":"Kuh","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2005.02.028_bib35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0168-3659(01)00308-X","article-title":"Determinants of drug delivery and transport to solid tumors","volume":"74","author":"Au","year":"2001","journal-title":"J. Control. Release"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365905001252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365905001252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T09:37:08Z","timestamp":1550741828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365905001252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["S0168365905001252"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2005.02.028","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}